返回 
加入收藏
CYP2C9*3基因多态性对苯溴马隆降尿酸疗效及其肝毒性的影响
x
请在关注微信后，向客服人员索取文件
| 篇名： | CYP2C9*3基因多态性对苯溴马隆降尿酸疗效及其肝毒性的影响 |
| TITLE： | Effects of CYP2C9*3 Gene Polymorphism on Therapeutic Efficacy of Benzbromarone in Lowering Uric Acid and Its Hepatotoxicity |
| 摘要： | 目的：研究CYP2C9*3基因多态性对苯溴马隆降尿酸疗效及其肝毒性的影响。方法：采用回顾性研究方法，对武汉市第三医院2018年1月－2019年9月196例服用苯溴马隆并行CYP2C9*3基因多态性检测的痛风患者的相关临床指标与基因型的相关性进行分析。结果：196例患者中，CYP2C9*3基因*1/*1、*1/*3、*3/*3基因型分别有179、15、2例，各基因型分布均符合Hardy-Weinberg遗传平衡定律（P＞0.05）。治疗前，*1/*1基因型患者的尿酸、血肌酐、丙氨酸转氨酶、天冬氨酸转氨酶、C反应蛋白水平与*1/*3+*3/*3基因型患者比较差异均无统计学意义（P＞0.05）；治疗4周后，*1/*1基因型患者的尿酸、血肌酐、C反应蛋白水平以及*1/*3+*3/*3基因型患者的尿酸、C反应蛋白水平均较治疗前显著降低，且*1/*1基因型患者尿酸水平显著低于*1/*3+*3/*3基因型患者（P＜0.05或P＜0.01）；不同基因型患者治疗前后丙氨酸转氨酶、天冬氨酸转氨酶水平均无明显变化（P＞0.05），且在正常范围内，治疗过程中未见肝功能严重异常者。结论：CYP2C9*3基因*1/*1基因型痛风患者使用苯溴马隆降尿酸的疗效较*1/*3、*3/*3基因型更好；而该基因多态性与该药肝毒性可能不相关。 |
| ABSTRACT： | OBJECTIVE：To study the effects o f CYP2C9*3 gene polymorphism on therapeutic efficacy of benzbromarone in lowering uric acid and its hepatotoxicity. METHODS ：A retrospective study was conducted to analyze the relevant clinical indicators and genotypes of 196 gout patients who received benzbromarone and CYP2C9*3 gene polymorphism test in Wuhan third hospital from Jan. 2018 to Sept. 2019. RESULTS ：Among 196 patients，179，15 and 2 patients with CYP2C9*3 genotypes * 1/*1， *1/*3 and * 3/*3 genotypes were found ，respectively，and the distribution of each genotype was in line with Hardy-Weinberg balance（P＞0.05）. Before treatment ，there were no significant differences in the levels of UA ，Scr，ALT，AST and CRP between *1/*1 genotype and * 1/*3+*3/*3 genotype（P＞0.05）. After 4 weeks of treatment ，the UA ，Scr，CRP levels of patients with * 1/*1 genotype as well as the UA and CRP levels of patients with * 1/*3+*3/*3 genotype were significantly reduced ，the UA level of patients with * 1/*1 genotype was significantly lower than that of patients with * 1/*3+*3/*3 genotype（P＜0.05 or P＜0.01）. The ALT and AST levels had no obvious changes in patients with different genotype before and after treatment ，and they were in the normal range. No serious abnormal liver function was observed during the treatment. CONCLUSIONS ：Therapeutic efficacy of benzbromarone in lowering uric acid in gout patients with CYP2C9*3 genotypes * 1/*1 genotype is better than that of * 1/*3 and * 3/*3 genotypes. However ，the gene polymorphism may be not associated with its hepatotoxicity. |
| 期刊： | 2021年第32卷第06期 |
| 作者： | 盛碧，孟军华，安靖，吴金虎，宋红艳，李江健，陈灵 |
| AUTHORS： | SHENG Bi，MENG Junhua ，AN Jing，WU Jinhu，SONG Hongyan ，LI Jiangjian ，CHEN Ling |
| 关键字： | CYP2C9*3；基因多态性；痛风；苯溴马隆；临床疗效；肝毒性 |
| KEYWORDS： | CYP2C9*3；Gene polymorphis m；Gout；Benzbromarone；Clinical efficacy ；Hepatotoxicity |
| 阅读数： | 330 次 |
| 本月下载数： | 10 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
